Filing Overview
Registrant: Intec Parent, Inc., a wholly owned subsidiary of Intec Pharma Ltd. The filing is a Form 8-K dated July 23, 2021, reporting corporate governance and organizational actions. The provided filing does not identify Indaptus Therapeutics, Inc. as the registrant.
Business Context and Reporting Period
The filing reports appointments to the board of directors and executive offices, formation of board committees, amendments to the certificate of incorporation and bylaws, and share-capital information for Intec Israel. It is not a periodic financial report and does not cover a financial quarter or year.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating expenses, guidance, or other financial performance metrics.
Material Corporate Changes
- Hila Karah, Anthony J. Maddaluna, William B. Hayes, and Dr. Roger J. Pomerantz were appointed directors on July 23, 2021.
- Dr. Roger J. Pomerantz was appointed chairman of the board. Jeffrey Meckler continued as a director.
- The board established Audit, Compensation, and Nominating committees and appointed their members and chairs.
- Jeffrey Meckler was designated Chief Executive Officer, Nir Sassi Chief Financial Officer, and Walt Linscott Chief Business Officer.
- The company adopted an amended and restated certificate of incorporation and amended and restated bylaws, effective immediately.
- As of July 23, 2021, Intec Israel had authorized share capital of 17.5 million ordinary shares and 7,370,883 ordinary shares outstanding.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. It does not disclose material contingencies, litigation, risk updates, or unusual financial items. The principal reported matters are governance, management appointments, and constitutional-document amendments.
Investor Verification Points
- Confirm the correct registrant, because the supplied metadata names Indaptus Therapeutics, Inc., while the filing identifies Intec Parent, Inc.
- Review Exhibits 3.1 and 3.2 for the detailed effects of the amended charter and bylaws.
- Verify the board’s classified-director terms and committee composition.
- Confirm Intec Israel’s share authorization and outstanding share count in the referenced July 23, 2021 filing.
- Consult the company’s periodic filings for financial condition, cash runway, debt, operating results, and business risks, which are not included here.